Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMN for Diabetic Kidney Disease
NCT05759468Phase 2Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Apr 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liposomal β-nicotinamide mononucleotide in diabetic kidney disease (DKD), sponsored by Brigham and Women's Hospital. Started Apr 2023; status: recruiting.
02
Drugs
liposomal β-nicotinamide mononucleotide
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT05759468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759468.